APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Cancer Vaccines and Therapeutics

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Selected research

Market Outlook & Growth Opportunities

Global mRNA Cancer Vaccines and Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchmRNA Cancer Vaccines and Therapeutics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Cancer Vaccines and Therapeutics Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal mRNA Cancer Vaccines and Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Cancer Vaccines and Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Cancer Vaccines and Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.

The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.

Read the full market overview

This report provides an overview of the global mRNA Cancer Vaccines and Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA Cancer Vaccines and Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Cancer Vaccines and Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global mRNA Cancer Vaccines and Therapeutics market.

mRNA Cancer Vaccines and Therapeutics Segment by Company

Moderna Therapeutics

CureVac

Translate Bio

BioNTech

Sangamo Therapeutics

Argos Therapeutics

In-Cell-Art

eTheRNA

Ethris

Tiba Biotechnology

mRNA Cancer Vaccines and Therapeutics Segment by Type

Adeno Carcinomas

Mucinous Carcinomas

Adenosquamous Carcinomas

mRNA Cancer Vaccines and Therapeutics Segment by Application

Infectious Disease

Cancer

Others

mRNA Cancer Vaccines and Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global mRNA Cancer Vaccines and Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the mRNA Cancer Vaccines and Therapeutics key companies, revenue, market share, and recent developments.

3. To split the mRNA Cancer Vaccines and Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions mRNA Cancer Vaccines and Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Cancer Vaccines and Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Cancer Vaccines and Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Cancer Vaccines and Therapeutics industry.

Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of mRNA Cancer Vaccines and Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of mRNA Cancer Vaccines and Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Cancer Vaccines and Therapeutics Industry Trends Table 2. mRNA Cancer Vaccines and Therapeutics Industry Drivers Table 3. mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges Table 4. mRNA Cancer Vaccines and Therapeutics Industry Restraints Table 5. Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2021-2026) Table 7. Global mRNA Cancer Vaccines and Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global mRNA Cancer Vaccines and Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global mRNA Cancer Vaccines and Therapeutics Company, Product Type & Application Table 10. Global mRNA Cancer Vaccines and Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global mRNA Cancer Vaccines and Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Adeno Carcinomas Table 15. Significant Companies of Mucinous Carcinomas Table 16. Significant Companies of Adenosquamous Carcinomas Table 17. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Infectious Disease Table 23. Significant Companies of Cancer Table 24. Significant Companies of Others Table 25. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global mRNA Cancer Vaccines and Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global mRNA Cancer Vaccines and Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global mRNA Cancer Vaccines and Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Moderna Therapeutics Company Information Table 41. Moderna Therapeutics Business Overview Table 42. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 44. Moderna Therapeutics Recent Development Table 45. CureVac Company Information Table 46. CureVac Business Overview Table 47. CureVac mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 49. CureVac Recent Development Table 50. Translate Bio Company Information Table 51. Translate Bio Business Overview Table 52. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 54. Translate Bio Recent Development Table 55. BioNTech Company Information Table 56. BioNTech Business Overview Table 57. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 59. BioNTech Recent Development Table 60. Sangamo Therapeutics Company Information Table 61. Sangamo Therapeutics Business Overview Table 62. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 64. Sangamo Therapeutics Recent Development Table 65. Argos Therapeutics Company Information Table 66. Argos Therapeutics Business Overview Table 67. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 69. Argos Therapeutics Recent Development Table 70. In-Cell-Art Company Information Table 71. In-Cell-Art Business Overview Table 72. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 74. In-Cell-Art Recent Development Table 75. eTheRNA Company Information Table 76. eTheRNA Business Overview Table 77. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 79. eTheRNA Recent Development Table 80. Ethris Company Information Table 81. Ethris Business Overview Table 82. Ethris mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 84. Ethris Recent Development Table 85. Tiba Biotechnology Company Information Table 86. Tiba Biotechnology Business Overview Table 87. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio Table 89. Tiba Biotechnology Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. mRNA Cancer Vaccines and Therapeutics Product Image Figure 2. Global mRNA Cancer Vaccines and Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global mRNA Cancer Vaccines and Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Adeno Carcinomas Image Figure 8. Mucinous Carcinomas Image Figure 9. Adenosquamous Carcinomas Image Figure 10. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Infectious Disease Image Figure 14. Cancer Image Figure 15. Others Image Figure 16. Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global mRNA Cancer Vaccines and Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Adeno Carcinomas
  • Mucinous Carcinomas
  • Adenosquamous Carcinomas
Applications
  • Infectious Disease
  • Cancer
  • Others
Companies covered
  • Moderna Therapeutics
  • CureVac
  • Translate Bio
  • BioNTech
  • Sangamo Therapeutics
  • Argos Therapeutics
  • In-Cell-Art
  • eTheRNA
  • Ethris
  • Tiba Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global mRNA Cancer Vaccines and Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 mRNA Cancer Vaccines and Therapeutics Market Dynamics
  1. 2.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
  2. 2.2 mRNA Cancer Vaccines and Therapeutics Industry Drivers
  3. 2.3 mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges
  4. 2.4 mRNA Cancer Vaccines and Therapeutics Industry Restraints
3 mRNA Cancer Vaccines and Therapeutics Market by Company
  1. 3.1 Global mRNA Cancer Vaccines and Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Cancer Vaccines and Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global mRNA Cancer Vaccines and Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global mRNA Cancer Vaccines and Therapeutics Company Product Type and Application
  6. 3.6 Global mRNA Cancer Vaccines and Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 mRNA Cancer Vaccines and Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 mRNA Cancer Vaccines and Therapeutics Market by Type
  1. 4.1 mRNA Cancer Vaccines and Therapeutics Type Introduction
  2. 4.1.1 Adeno Carcinomas
  3. 4.1.2 Mucinous Carcinomas
  4. 4.1.3 Adenosquamous Carcinomas
  5. 4.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type
  6. 4.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type (2021-2032)
5 mRNA Cancer Vaccines and Therapeutics Market by Application
  1. 5.1 mRNA Cancer Vaccines and Therapeutics Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.1.3 Others
  5. 5.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application
  6. 5.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application (2021-2032)
6 mRNA Cancer Vaccines and Therapeutics Regional Value Analysis
  1. 6.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Sales Value Share by Country, 2025 VS 2032
7 mRNA Cancer Vaccines and Therapeutics Country-level Value Analysis
  1. 7.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global mRNA Cancer Vaccines and Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt mRNA Cancer Vaccines and Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt mRNA Cancer Vaccines and Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt mRNA Cancer Vaccines and Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Moderna Therapeutics
  2. 8.1.1 Moderna Therapeutics Company Information
  3. 8.1.2 Moderna Therapeutics Business Overview
  4. 8.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
  6. 8.1.5 Moderna Therapeutics Recent Developments
  7. 8.2 CureVac
  8. 8.2.1 CureVac Company Information
  9. 8.2.2 CureVac Business Overview
  10. 8.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio
  12. 8.2.5 CureVac Recent Developments
  13. 8.3 Translate Bio
  14. 8.3.1 Translate Bio Company Information
  15. 8.3.2 Translate Bio Business Overview
  16. 8.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio
  18. 8.3.5 Translate Bio Recent Developments
  19. 8.4 BioNTech
  20. 8.4.1 BioNTech Company Information
  21. 8.4.2 BioNTech Business Overview
  22. 8.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio
  24. 8.4.5 BioNTech Recent Developments
  25. 8.5 Sangamo Therapeutics
  26. 8.5.1 Sangamo Therapeutics Company Information
  27. 8.5.2 Sangamo Therapeutics Business Overview
  28. 8.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
  30. 8.5.5 Sangamo Therapeutics Recent Developments
  31. 8.6 Argos Therapeutics
  32. 8.6.1 Argos Therapeutics Company Information
  33. 8.6.2 Argos Therapeutics Business Overview
  34. 8.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
  36. 8.6.5 Argos Therapeutics Recent Developments
  37. 8.7 In-Cell-Art
  38. 8.7.1 In-Cell-Art Company Information
  39. 8.7.2 In-Cell-Art Business Overview
  40. 8.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio
  42. 8.7.5 In-Cell-Art Recent Developments
  43. 8.8 eTheRNA
  44. 8.8.1 eTheRNA Company Information
  45. 8.8.2 eTheRNA Business Overview
  46. 8.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio
  48. 8.8.5 eTheRNA Recent Developments
  49. 8.9 Ethris
  50. 8.9.1 Ethris Company Information
  51. 8.9.2 Ethris Business Overview
  52. 8.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio
  54. 8.9.5 Ethris Recent Developments
  55. 8.10 Tiba Biotechnology
  56. 8.10.1 Tiba Biotechnology Company Information
  57. 8.10.2 Tiba Biotechnology Business Overview
  58. 8.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio
  60. 8.10.5 Tiba Biotechnology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst